Recent Advances in Inflammation & Allergy Drug Discovery最新文献

{"title":"Apremilast in Psoriasis: Current Landscape and Perspectives.","authors":"Dinesh Kumar, Debayan Sil, Balak Das Kurmi, Manish Kumar","doi":"10.2174/0127722708351802250717104057","DOIUrl":"https://doi.org/10.2174/0127722708351802250717104057","url":null,"abstract":"<p><p>Psoriasis is an immune-mediated skin disease manifested in more than 3% of Americans and over 125 million people worldwide. The inflammatory skin condition with an increased rate of keratinocyte turnover involves every level of the skin and exhibits various forms of the disease, including plaque, guttate, inverse, pustular, and erythrodermic psoriasis, as well as disease-associated conditions, such as psoriatic arthritis and nail psoriasis. Innovative treatment has highlighted the importance of Apremilast, an oral drug that belongs to the phosphodiesterase- 4 (PDE4) class, which was approved by the FDA in 2014. Apremilast works by increasing the presence of cyclic adenosine monophosphate (cAMP) within cells, thereby affecting inflammatory processes and reducing the production of pathological cytokines. Randomized controlled trials have shown that it effectively treats moderately to severely affected plaque psoriasis and psoriatic arthritis, and it is safer than traditional systemic agents. The new perspective on the usage of ethosomes, niosomes, liposomes, and nanostructured lipid carriers in psoriasis treatment is based on emerging nanotechnology in drug delivery systems. These new formulations are designed to enhance the solubility and targeted release of Apremilast, thus providing an enhanced therapeutic effect. This review will discuss the basic mechanisms of the disease known as psoriasis, as well as the mode of operation, pharmacological properties, clinical trials, and pharmacokinetics of apremilast, particularly in relation to nanocarrier modification of this promising drug.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vanillin: A Review on the Therapeutic Potential as an Anti-inflammatory Agent.","authors":"Sonia Singh, Bhupesh Chander Semwal, Bhoopendra Singh, Aditya Pratap Singh, Siva Prasad Panda","doi":"10.2174/0127722708368753250713180110","DOIUrl":"https://doi.org/10.2174/0127722708368753250713180110","url":null,"abstract":"<p><p>Vanillin is a naturally occurring compound found in numerous plant species and is commonly utilized in food, beverages, cosmetics, and pharmaceuticals. It is the main ingredient in vanilla pods, and numerous studies have indicated that it has a variety of pharmacological properties, including anti-inflammatory, antioxidant, and anticancer properties. Vanillin is extensively utilized in modern drug research for the treatment of many diseases, including cancer, due to its anti-inflammatory properties. Besides its application in food and flavoring, vanillin acts as a precursor in the production of other valuable petroleum-derived chemicals. This review provides a thorough explanation of the impact of this phytochemical on many signalling pathways, which are interconnected with the root cause of disease. This review also discusses its pharmacokinetic characteristics and clinical trial studies.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144754642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological Characterization of Ruellia tuberosa Ethanolic Extract in a Rodent Model of Cognitive Impairment.","authors":"Rahul Kumar, Nidhi Tyagi","doi":"10.2174/0127722708364435250604032539","DOIUrl":"https://doi.org/10.2174/0127722708364435250604032539","url":null,"abstract":"<p><strong>Introduction: </strong>Cognitive impairment linked to neurodegenerative diseases poses a considerable challenge, requiring the exploration of plant-derived therapeutic alternatives. Ruellia tuberosa, a medicinal plant recognized for its anti-oxidant and anti-inflammatory properties, was examined for its therapeutic potential in a rodent model of memory impairment.</p><p><strong>Method: </strong>The present study aimed to evaluate the effects of Ruellia tuberosa ethanolic extract (RTEE) on aluminium chloride (AlCl3)-induced Alzheimer's disease (AD) in adult Wistar rats. In-vitro cell line study showed decreased formation of reactive oxygen species (ROS), decreased levels of IL-6 (Interleukin-6), and suppressed NF-κB (Nuclear factor kappa-B) translocation, which further confirmed RTEE's antioxidant and anti-inflammatory characteristics. Following the objective, thirty adult Wistar rats were taken and divided into five groups (n=6). They were treated with Normal saline, AlCl3 (100 mg/kg), DPZ (Donepezil- 3 mg/kg), and RTEE (100 and 200 mg/kg), respectively, for 35 days.</p><p><strong>Results: </strong>Various behavioral and biochemical parameters, along with the oxidative and inflammatory biomarkers, were assessed to determine the effects of RTEE. The plant extract at both the doses (100 and 200 mg/kg) demonstrated increased body weight, improved motor coordination as demonstrated by an increase in fall-off time on the Rota rod apparatus, decreased escape latency in the Morris water maze test, reduced transfer latency (TL) in the elevated plus maze test, increased time spent in the target quadrant, and increased exploration time in the novel object recognition test. Furthermore, RTEE treatment exhibited decreased levels of malondialdehyde (MDA) and acetylcholinesterase (AChE) activity and increased levels of glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and total protein. Additionally, RTEE reduced levels of inflammatory cytokines, such as TNF-α and IL-1β, which decreased neuroinflammation and amyloid-beta levels. Additionally, the extract exhibited cholinergic system modulation, as observed by improved acetylcholinesterase activity, suggesting its potential role in neurotransmitter regulation. Histopathological study further confirmed its neuroprotective potential by reducing neuronal degeneration in brain regions (hippocampus and cortex).</p><p><strong>Conclusion: </strong>According to the study's findings, memory impairment in the AlCl3-induced rat model of AD was ameliorated by both doses of RTEE. However, further studies need to be conducted to establish its therapeutic effects in neurodegenerative diseases.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alzheimer's Disease and Inflammation Research: A Systematic Bibliometric Review and Network Visualization of the Published Literature Between 2000 and 2023.","authors":"Khairunnuur Fairuz Azman, Che Aishah Nazariah Ismail, Nazlahshaniza Shafin, Rahimah Zakaria","doi":"10.2174/0127722708363344250529050252","DOIUrl":"https://doi.org/10.2174/0127722708363344250529050252","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and memory loss. In recent years, inflammation has gained recognition as a key contributor to both the onset and progression of Alzheimer's disease, acting through complex pathways that include neuroinflammation and immune system dysregulation. This study aims to systematically review the relationship between Alzheimer's disease and inflammation, focusing on publication trends from 2000 to 2023.</p><p><strong>Methods: </strong>Using the Scopus database, a bibliometric analysis was conducted through Microsoft Excel, Harzing's Publish or Perish, and VOSviewer, examining publication trends, citation metrics, and co-network visualization.</p><p><strong>Results: </strong>A total of 1,205 relevant publications were identified, revealing a steady increase in research output. The majority of contributions came from the United States (33.1%), China (16.8%), and the United Kingdom (8.8%). Key terms such as \"neuroinflammation\", \"cytokine\", \"microglia\", \"amyloid beta\", and \"oxidative stress\" dominated the literature, while emerging keywords included \"neuroprotection\", \"BDNF\", \"inflammasome\", and \"mitochondria\".</p><p><strong>Conclusion: </strong>These findings underscore the growing focus on the role of inflammatory processes in the etiopathology of Alzheimer's disease, as well as efforts to identify biomarkers and neuroprotective therapeutic targets. This study provides a detailed mapping of the research landscape, offering insights into the evolving knowledge structure and highlighting prominent countries, institutions, authors, journals, and highly cited articles. By identifying key trends, this review advances our understanding of the interplay between inflammation and Alzheimer's disease, paving the way for future research and clinical strategies.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144286645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Analysis between Lymphocytic Esophagitis and Eosinophilic Esophagitis: A Retrospective Cross-Sectional Study.","authors":"Mukundkumar V Patel, Maitri M Patel, Dhara K Patel, Dhruvkumar M Patel, Lalitkumar B Patel, Sanjay Rajput","doi":"10.2174/0127722708341294250509063835","DOIUrl":"https://doi.org/10.2174/0127722708341294250509063835","url":null,"abstract":"<p><strong>Background: </strong>Lymphocytic Esophagitis (LyE) and Eosinophilic Esophagitis (EoE) share many clinical and endoscopic features. However, their treatment outcomes and prognoses differ significantly. LyE, the least recognized form of esophagitis, requires further research. This study compares symptoms, risk factors, and endoscopic findings in LyE and EoE patients.</p><p><strong>Methods: </strong>This study reviewed medical records, esophagogastroduodenoscopy (EGD) findings, and biopsy data. Patients aged 18 years and older who underwent EGD-guided segmental esophageal biopsies between March 2018 and January 2024 were included. Demographic data, clinical features, risk factors, and EGD findings were compared between LyE, EoE, non-specific esophagitis (NSE), and normal esophageal histology (NEH) groups. The NSE and NEH groups served as controls.</p><p><strong>Results: </strong>The cohort included 11 LyE cases (1.25%), 79 EoE cases (8.96%), 447 NSE cases (50.68%), and 345 NEH cases (3.11%). LyE patients were older, with a mean age of 54.81 years, and 72.72% of them were female. In contrast, EoE patients were younger, with a mean age of 43.52 years, and had a male predominance. Cases of dysphagia, dyspepsia, and nausea or vomiting occurred in both groups. Food impaction was more frequent in EoE. Smoking, alcohol use, and autoimmune diseases (e.g., hypothyroidism and rheumatoid arthritis) were significant risk factors for LyE. Atopic conditions such as asthma and allergies were linked to EoE. Endoscopic findings often overlapped in LyE and EoE. Esophagitis and strictures were more common in LyE, while rings and furrows were more frequent in EoE. All endoscopic findings, including normal mucosa, were significant in LyE and EoE compared to controls. However, rings, linear furrows, and exudates were not significant when comparing LyE to controls.</p><p><strong>Conclusion: </strong>LyE is a rare form of esophagitis with clinical and endoscopic features similar to EoE. Accurate histopathological diagnosis is essential for differentiation. LyE is more common in older females with autoimmune conditions, while EoE affects younger males with atopic conditions.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Inflammatory Bowel Disease Activity by Non-invasive Biomarkers: Still a Long Way Ahead.","authors":"Stefano Fiorucci, Ginevra Urbani","doi":"10.2174/0127722708402763250424092507","DOIUrl":"https://doi.org/10.2174/0127722708402763250424092507","url":null,"abstract":"","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Individual and Cassette Administration on Pharmacokinetics of Prednisolone, Diclofenac, and Methotrexate in a Rodent Model of Rheumatoid Arthritis.","authors":"Satish Kumar, Surendra Yadav Ravulapalli, Satinder Singh, Sumeet Gupta, Pratima Srivastava","doi":"10.2174/0127722708344359250414035502","DOIUrl":"https://doi.org/10.2174/0127722708344359250414035502","url":null,"abstract":"<p><strong>Objectives: </strong>To find out how arthritic diseases affect the pharmacokinetics of prednisolone, diclofenac, and methotrexate when given individually and as a cassette in male Sprague- Dawley rats, the study's main goal was to look into drug-drug interactions (DDI). For the treatment of moderate to severe arthritis, doctors commonly prescribe all three drugs alone or in combination.</p><p><strong>Methodology: </strong>Pharmacokinetics (PK) was evaluated using individual and cassette dosing in male Sprague-Dawley rats in a fasting state. Respective experimental groups were administered orally with prednisolone (5.0 mg/kg), diclofenac (10.0 mg/kg), and methotrexate (0.5 mg/kg) during either discrete or cassette dosing, at a dose volume of 5 mL/kg. Blood samples were collected through the jugular vein and analyzed by liquid chromatography-tandem mass spectrometry. Pharmacokinetics parameters were calculated using Phoenix software version 8.1.</p><p><strong>Results: </strong>Prednisolone significantly decreased the AUC0-last in both the arthritic group and the cassette group when compared to the standalone normal animal group. Neither cassette dosing in the normal group nor discrete dosing in the arthritic group affected the pharmacokinetics (PK) of diclofenac. However, the AUC0-last value for diclofenac significantly decreased during cassette dosing in the arthritic group. Individual administration of methotrexate in the arthritic group resulted in a significant decrease in AUC0-last, while the healthy group experienced a substantial increase when administered as a cassette.</p><p><strong>Conclusion: </strong>Along with the pharmacological DDI, this study looked at how disease affected the PK of prednisolone, diclofenac, and methotrexate when these drugs were given in both discrete and cassette doses. Significant differences in AUC0-t and Cmax of prednisolone and methotrexate pharmacokinetics when dozed as a cassette or individually in arthritic groups were noticed. The serum concentration of methotrexate increased when it was combined with diclofenac. Further, the metabolism of methotrexate increased when combined with prednisolone.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Medicinal Chemistry of Phosphodiesterase 7 Inhibitors and their Potential Therapeutic Applications.","authors":"Rishab Bhanot, Ajmer Singh Grewal, Anjana Devi","doi":"10.2174/0127722708362767250410094814","DOIUrl":"https://doi.org/10.2174/0127722708362767250410094814","url":null,"abstract":"<p><strong>Introduction: </strong>Phosphodiesterase 7 (PDE7) is a key enzyme in the PDE superfamily responsible for degrading cyclic adenosine monophosphate (cAMP) in pro-inflammatory and immunomodulatory cells. Elevated PDE7 activity is associated with inflammatory processes and various diseases. Suppression of PDE7 raises cAMP levels, reducing mucous secretion, cellular inflammation, and airway obstruction.</p><p><strong>Objective: </strong>This review provides an overview of the role of PDE7 in inflammatory disorders and highlights recent advances in the development of selective PDE7 inhibitors for therapeutic applications.</p><p><strong>Methods: </strong>The review consolidates findings on the structure-activity relationships of PDE7 inhibitors. Key structural classes of small molecule inhibitors, including quinazolinone derivatives, thiadiazines, pyrimidines, and others, are discussed alongside preclinical and clinical data on selective inhibitors such as BRL50481 and OMS527.</p><p><strong>Results: </strong>Selective PDE7 inhibitors have shown exposed potential in animal models to reduce cAMP degradation, leading to decreased inflammation and airway obstruction. BRL50481 remains the only commercially available selective PDE7 inhibitor, while OMS527 has progressed to clinical trials, demonstrating promise in treating inflammatory, neurological disorders, and leukemias.</p><p><strong>Conclusion: </strong>Selective PDE7 inhibitors represent a novel therapeutic class for inflammatory and neurodegenerative diseases. Further research is characterised by immune dysregulation.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Unseen Dangers: The Effects of Micro- and Nanoplastics on Human Reproductive Health - A Narrative Review\".","authors":"Naina Kumar","doi":"10.2174/0127722708359509250331150754","DOIUrl":"https://doi.org/10.2174/0127722708359509250331150754","url":null,"abstract":"<p><p>Micro(nano)plastics (MNPs) have become pervasive environmental pollutants due to widespread use and inadequate waste management practices. These tiny particles infiltrate various ecosystems, including the human body, raising significant concerns about their potential health effects. Of particular concern is their impact on human reproductive health, with emerging research indicating MNPs' ability to breach biological barriers, accumulate in reproductive organs, and potentially reach the placenta. A comprehensive literature search spanning from July 2015 to July 2024 was conducted across prominent electronic databases, including Pub- Med, Scopus, Web of Science, and Google Scholar. Key search terms such as \"micro and nanoplastics,\" \"microplastics and male reproductive health,\" \"microplastics and female reproductive health,\" \"transgenerational spread of microplastics,\" and \"microplastics and fetal health\" were used to identify relevant studies published in peer-reviewed journals, books, and reputable conference proceedings. Selection criteria favoured review articles, original research papers, metaanalyses, and authoritative texts published in English. Synthesized findings from these studies were critically analysed to underscore their potential impacts on reproductive health. The accumulating evidence emphasizes the urgent need for further research to fully grasp the risks posed by MNPs to human reproductive health. Effective mitigation strategies are essential to minimize exposure and mitigate potential long-term consequences. Policy interventions aimed at enhancing waste management practices and regulating plastic usage are crucial to curb the environmental spread of MNPs and safeguard human reproductive health effectively.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological Management of Psoriasis: Current Landscape and Future Perspectives.","authors":"Roopal Pedwar, Anush Tomar, Sweta Bawari","doi":"10.2174/0127722708338282250309081129","DOIUrl":"https://doi.org/10.2174/0127722708338282250309081129","url":null,"abstract":"<p><p>Psoriasis is a relapsing, chronic, and inflammatory disease of the skin. However, its impact goes beyond just pathophysiology and takes a toll on the physical and psychological aspects of the health of the afflicted, lowering the quality of life significantly. It is also a mechanistically complex disease with a substantial immune component. Therefore, ongoing treatment strategies focus on targeting at least one immune component associated with the disease development and progression by employing biological agents like IL-1 inhibitors, IL-23 inhibitors, IL-36 inhibitors, and TNF-α inhibitors. Psoriasis-induced disruptions in cellular signalling pathways have drawn significant attention as novel drug targets. Numerous novel synthetic agents, such as JAK/STAT inhibitors [ruxolitinib, peficitinib], TYK2 inhibitors [zasocitinib, ropsacitinib], RORꝩT inhibitors [cedirogant], A3AR agonists [piclodenoson], and CXCR2 antagonists [vimnerixin] are undergoing extensive clinical trials and have demonstrated beneficial outcomes in multiple phases of these trials. Deucravacitinib, an orally administered TYK2 inhibitor, has recently received FDA approval for the treatment of moderate to severe plaque psoriasis. These synthetic agents hold promise to change the outlook of psoriasis management by modulating specific molecular targets associated with the dysregulated immune response observed in psoriasis. Moreover, these pathways can be exploited to personalize anti-psoriatic therapy, minimize side effects, and maximize therapeutic outcomes. Altogether, the integration of biological agents and synthetic agents can overcome the challenges associated with the management of the repertoire of psoriatic pathophysiology and symptoms.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}